In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 5, 2007, Pages 1021-1024

  Venkatesh, Pilla Reddy ^a   Goh, Evelyn ^a   Zeng, Peizi ^a   New, Lee Sun ^a   Xin, Liu ^a   Pasha, Mohammed Khalid ^a   Sangthongpitag, Kanda ^a   Yeo, Pauline ^a   Kantharaj, Ethirajulu ^a  

^a S BIO Pte Ltd   (Singapore)

Author keywords

Bioavailability; Histone deacetylase (HDAC); Mouse; Pharmacokinetics; SB639; Suberoylanilide hydroxamic acid (SAHA)

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; SB 639; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL STRAIN CACO 2; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MAXIMUM ALLOWABLE CONCENTRATION; MONOLAYER CULTURE; MOUSE; NONHUMAN; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; METABOLIC DETOXICATION, PHASE I; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; PYRROLES; RATS; RATS, WISTAR;

EID: 34248220985     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.1021     Document Type: Article

References (14)

1. Liu R. J., Nagy L., Inoue S., Shao W., Miller W. H., Evans R. M., Nature (London), 391, 811-814 (1998).
2. Yoo C. B., Jones P.A., Nat. Rev. Drug Discov., 5, 37-50 (2006).
3. Marks P. A., Rifkind R. A., Richon V. M., Breslow R., Miller T., Kelly W. K., Nat. Rev. Cancer, 1, 194 (2001).
4. Vigushin D. M., Coombes R. C., Curr. Cancer Drug Targets, 4, 205-218 (2004).
5. Marks P. A., Rifkind, Richon R. A., Breslow V. M., Miller R. T., Kelly W. K., Adv. Cancer Res., 91, 137-168 (2004).
6. Qian, D. Z., Wang X., Kachhap S. K., Kato Y., Wei Y., Zhang L., Atadja P., Pili R., Cancer Res., 64, 6626-6634 (2004).
7. O'Connor O. A., Heaney M. L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., Curly T., Moskowitz C., Portlock C., Horwitz S., Zelenetz A. D., Frankel S., Richon V., Marks P., Kelly W. K., J. Clin. Oncol., 24, 166-173 (2006).
8. Kelly W. K., O'Connor O. A., Krug L., J. Clin. Onco., 23, 3923-3931 (2005).
9. Talpur C., Zhang A., Goy V., Am. Soc. Clin. Oncol., 23, 577 (2005).
10. Butler L. M., Agus D. B., Scher H. I., Cancer Res., 60, 5165-5170 (2000).
11. Obach R. S., Drug Met. Disp., 27, 1350-1359 (1999).
12. http://www.fda.gov/cder/foi/nda/2006/021991s000_Zolinza_PharmR.pdf
13. Gibaldi M., Perrier D., "Pharmacokinetics," 2nd ed., Marcel Dekker publishers, New York, 1982, pp. 409-417.
14. Yeo P., Xin L., Goh E., New L. S., Zeng P., Wu X., Venkatesh P., Kantharaj E., Biomedical Chrom., 21, 184-189 (2007).